Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Sriwijaya Journal of Ophthalmology Sriwijaya Journal of Radiology and Imaging Research
Oliva Azalia Putri
Department of Surgery, CMHC Research Center, Palembang, Indonesia
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Medicine & Pharmacology Neuroscience Physics

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Sustained Anti-VEGF Delivery via Hydrogel Implant Achieves Non-Inferior Visual and Anatomical Outcomes in Neovascular AMD: A 24-Month Randomized Controlled Trial Habiburrahman Said; Oliva Azalia Putri; Linda Purnama
Sriwijaya Journal of Ophthalmology Vol. 8 No. 2 (2025): Sriwijaya Journal of Ophthalmology
Publisher : Department of Opthalmology, Faculty of Medicine, Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/sjo.v8i2.138

Abstract

Introduction: Neovascular age-related macular degeneration (nAMD) requires frequent anti-VEGF intravitreal injections, creating substantial treatment burden. This study compared the 24-month efficacy and safety of a sustained-release anti-VEGF hydrogel implant versus monthly ranibizumab in treatment-naive nAMD eyes. Methods: This prospective randomized controlled trial enrolled 126 eyes (96 patients; 30 bilateral) with treatment-naive nAMD at a private hospital in Palembang, Indonesia (January 2022–December 2024). Eyes were randomized 1:1 to a biodegradable anti-VEGF hydrogel implant (n=64) or monthly ranibizumab 0.5 mg (n=62). The primary outcome was non-inferiority of the mean best-corrected visual acuity (BCVA) change (LogMAR) at 24 months (margin: 0.10 LogMAR). Analyses used linear mixed-effects models with generalized estimating equations to account for inter-eye correlation. Results: Mean BCVA improved by −0.24±0.18 LogMAR (≈12 letters) in the hydrogel group and −0.22±0.20 LogMAR (≈11 letters) in the ranibizumab group (difference: −0.02; 95% CI: −0.09 to 0.05; p=0.578; non-inferiority confirmed). The hydrogel group required 77.8% fewer injections (4.8±1.2 vs 21.6±3.4; p<0.001). Safety profiles were comparable. Conclusion: The sustained-release anti-VEGF hydrogel implant achieved non-inferior visual and anatomical outcomes versus monthly ranibizumab while reducing injection burden by 77.8% over 24 months. Multicenter validation is warranted.
Deep-Learning Pharmacokinetic Modelling for Personalised Low-Dose Gadolinium in Oncological 3.0-T MRI: A Diagnostic-Accuracy Study Oliva Azalia Putri; Sony Sanjaya
Sriwijaya Journal of Radiology and Imaging Research Vol. 3 No. 2 (2025): Sriwijaya Journal of Radiology and Imaging Research
Publisher : Phlox Institute: Indonesian Medical Research Organization

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59345/sjrir.v3i2.290

Abstract

Introduction: Weight-based dosing of gadolinium-based contrast agents (GBCA; 0.1 mmol/kg) in oncological MRI disregards individual haemodynamics and tumour microvascularity, contributing to avoidable cumulative exposure and tissue-retention risk. We evaluated an artificial-intelligence (AI)-assisted pharmacokinetic-modelling approach to personalise and reduce GBCA dose while preserving diagnostic performance. Methods: In this prospective, paired diagnostic-accuracy study reported per STARD 2015 at a tertiary hospital in Palembang, Indonesia, 152 adults (198 lesions) with histologically confirmed solid primary malignancies underwent 3.0-T contrast-enhanced MRI. A convolutional-neural-network extended-Tofts model derived each patient’s minimum effective gadobutrol dose, compared against the standard 0.1 mmol/kg protocol. Two radiologists, blinded to clinical data and to a composite reference standard (histopathology and ≥6-month imaging follow-up), assessed signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), 5-point diagnostic confidence and lesion characterisation. Sensitivity, specificity, AUC (DeLong), likelihood ratios, Cohen’s κ and McNemar testing were computed with 95% confidence intervals. Results: The AI protocol reduced GBCA dose by 38.4% (4.6 vs 7.5 mL; p<0.001). Sensitivity was 95.2% (95% CI 90.9–97.6), specificity 83.3% (66.4–92.7) and AUC 0.94 (0.90–0.97) versus 0.95 (0.91–0.98) for standard dose (DeLong p=0.620; McNemar p=0.773). SNR and CNR were non-inferior (all p>0.05). Inter-reader agreement was substantial-to-almost-perfect (characterisation κ 0.83; confidence κ 0.88). Diagnostic adequacy was maintained in 149/152 cases (98%). Conclusion: AI-assisted pharmacokinetic modelling enabled a 38% gadolinium-dose reduction without loss of diagnostic accuracy or image quality, supporting personalised contrast administration and lower cumulative exposure in oncological MRI.
Sustained Anti-VEGF Delivery via Hydrogel Implant Achieves Non-Inferior Visual and Anatomical Outcomes in Neovascular AMD: A 24-Month Randomized Controlled Trial Habiburrahman Said; Oliva Azalia Putri; Linda Purnama
Sriwijaya Journal of Ophthalmology Vol. 8 No. 2 (2025): Sriwijaya Journal of Ophthalmology
Publisher : Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/sjo.v8i2.138

Abstract

Introduction: Neovascular age-related macular degeneration (nAMD) requires frequent anti-VEGF intravitreal injections, creating substantial treatment burden. This study compared the 24-month efficacy and safety of a sustained-release anti-VEGF hydrogel implant versus monthly ranibizumab in treatment-naive nAMD eyes. Methods: This prospective randomized controlled trial enrolled 126 eyes (96 patients; 30 bilateral) with treatment-naive nAMD at a private hospital in Palembang, Indonesia (January 2022–December 2024). Eyes were randomized 1:1 to a biodegradable anti-VEGF hydrogel implant (n=64) or monthly ranibizumab 0.5 mg (n=62). The primary outcome was non-inferiority of the mean best-corrected visual acuity (BCVA) change (LogMAR) at 24 months (margin: 0.10 LogMAR). Analyses used linear mixed-effects models with generalized estimating equations to account for inter-eye correlation. Results: Mean BCVA improved by −0.24±0.18 LogMAR (≈12 letters) in the hydrogel group and −0.22±0.20 LogMAR (≈11 letters) in the ranibizumab group (difference: −0.02; 95% CI: −0.09 to 0.05; p=0.578; non-inferiority confirmed). The hydrogel group required 77.8% fewer injections (4.8±1.2 vs 21.6±3.4; p<0.001). Safety profiles were comparable. Conclusion: The sustained-release anti-VEGF hydrogel implant achieved non-inferior visual and anatomical outcomes versus monthly ranibizumab while reducing injection burden by 77.8% over 24 months. Multicenter validation is warranted.
Co-Authors Habiburrahman Said Linda Purnama Sony Sanjaya